Inmed Pharmaceuticals Inc reports a Return on Equity (ROE) of -143.83%.

What is INM's dividend yield?

Inmed Pharmaceuticals Inc offers a dividend yield of 0.00%.

What is INM's Quality Score?

Our AI rates INM's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy INM?

Our AI Timing Score for INM is 69 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does INM belong to?

Inmed Pharmaceuticals Inc is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange

Inmed Pharmaceuticals Inc (INM) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

INM AI Analysis Summary

Our AI summary for INM: Inmed Pharmaceuticals Inc (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 0.00, ROE of -143.83%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 69/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

INM

Inmed Pharmaceuticals Inc

USD 1.40

-0.09 (-6.04%) Day Change

Watchlist Portfolio Compare Chart

0.06

D/E

-143.8%

ROE

-108.5%

ROA

0.00%

Div Yield

INMED PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.40 Price -0.09 (-6.04%) Day Change	NEWS SCORE: 94

INM, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	94
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.40
PBV / Sector	1.15 / 10.19 GREAT
Earning Per Share	-1.74

PE / Sector	N/A / 31.74
PEG or PE/Growth / Sector	N/A / -0.02
Average 1M Daily Value	4.55 M GREAT
Average 1W Daily Value	0.22 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-1.49 / 12.63
NPM Average (%) / Sector	-446.61 / -10.74
NPM Change Average (%) / Sector	-50.51 / 114.91
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-108.52 / 7.67
ROA Average (%) / Sector	-69.99 / 2.97
ROA Change Average (%) / Sector	28.12 / 112.43 GREAT
ROE (%) / Sector	-143.83 / 25.75
ROE Average (%) / Sector	-91.63 / 14.00
ROE Change Average (%) / Sector	37.43 / 378.64 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.52
Dividend Average (%) / Sector	N/A / 3.06
Dividend Change Average (%) / Sector	N/A / 13.74

Registration Details

Analyze Date	2026-08-06 08:00:10
Symbol	INM
Name	INMED PHARMACEUTICALS INC
Sector	Healthcare >> Drug Manufacturers - Specialty & Generic
Market	NASDAQ
Listed Shares	5.34 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	7.96 / 10,556.24

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8

Phone: 604 669 7207

Website: https://www.inmedpharma.com

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.